BRIEF published on 11/12/2026 at 07:35, 1 day 6 hours ago Le segment des produits pharmaceutiques de marque de Dermapharm soutient sa croissance Croissance Des Revenus Augmentation De L'EBITDA Dermapharm Médicaments De Marque Perspectives Pour 2026
BRIEF published on 11/12/2026 at 07:35, 1 day 6 hours ago Dermapharm's Branded Pharmaceuticals Segment Bolsters Growth Revenue Growth EBITDA Increase Branded Pharmaceuticals Dermapharm 2026 Outlook
PRESS RELEASE published on 11/12/2026 at 07:30, 1 day 6 hours ago Strong existing business in the "Branded pharmaceuticals" segment drives positive performance
BRIEF published on 08/25/2026 at 07:35, 2 months 19 days ago Dermapharm Reports Profitable Growth in H1 2026 EBITDA Increase Pharmaceutical Growth Branded Pharmaceuticals Dermapharm H1 2026 Results
BRIEF published on 08/25/2026 at 07:35, 2 months 19 days ago Dermapharm annonce une croissance rentable au premier semestre 2026 Augmentation De L'EBITDA Croissance Pharmaceutique Dermapharm Médicaments De Marque Résultats Du Premier Semestre 2026
PRESS RELEASE published on 08/25/2026 at 07:30, 2 months 19 days ago Dermapharm confirms profitable growth in H1 2026 and increases adjusted EBITDA Dermapharm Holding SE reports 2.9% revenue growth and 10.3% increase in adjusted EBITDA for H1 2026. Strong performance in branded pharmaceuticals and healthcare products segments Adjusted EBITDA Revenue Growth Pharmaceuticals Dermapharm Holding SE Healthcare Products
BRIEF published on 08/11/2026 at 07:35, 3 months 2 days ago Dermapharm Reports Strong Profits and Confirms 2026 Guidance Revenue Growth EBITDA Increase Dermapharm First Half 2026 Pharmaceuticals Segment
BRIEF published on 08/11/2026 at 07:35, 3 months 2 days ago Dermapharm annonce des bénéfices solides et confirme ses prévisions pour 2026 Croissance Des Revenus Augmentation De L'EBITDA Dermapharm Segment Pharmaceutique Premier Semestre 2026
PRESS RELEASE published on 08/11/2026 at 07:30, 3 months 2 days ago Dermapharm Holding SE reports profitable growth in H1 2026 and confirms guidance Dermapharm Holding SE reports 2.9% revenue growth in H1 2026, with unadjusted EBITDA up by 27.3%. Company confirms guidance for 2026 EBITDA Revenue Growth Pharmaceuticals Dermapharm Holding SE 2026 Guidance
BRIEF published on 06/26/2026 at 13:35, 4 months 17 days ago Dermapharm approuve un dividende de 0,88 EUR, sa croissance se poursuivant. Dividende Stratégie De Croissance Soins De Santé Assemblée Générale Annuelle Dermapharm
Published on 11/13/2026 at 14:00, 14 minutes ago GameSquare's Hatchet Publishes TikTok Live for Gaming in H1 2026 Report
Published on 11/13/2026 at 13:30, 44 minutes ago Mako Mining Reports Q3 2026 Financial Results, Including Adjusted EBITDA(1) of US$30.3 million and EPS of US$0.19/share
Published on 11/13/2026 at 13:30, 44 minutes ago Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
Published on 11/13/2026 at 10:40, 3 hours 34 minutes ago SouthGobi Announces Third Quarter 2026 Unaudited Financial and Operating Results
Published on 11/13/2026 at 09:00, 5 hours 14 minutes ago Touchstone Exploration Announces Third Quarter 2026 Results
Published on 11/13/2026 at 13:30, 44 minutes ago Cemig and Huawei Jointly Deploy 450 MHz Private Wireless Network
Published on 11/13/2026 at 12:30, 1 hour 44 minutes ago WIN SOURCE Highlights NEXUS™ at electronica 2026, Advancing Supply Chain Resilience
Published on 11/13/2026 at 12:30, 1 hour 44 minutes ago Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Published on 11/13/2026 at 12:10, 2 hours 4 minutes ago Where Winds Meet 1st Anniversary Launches Today: New 'Hutuo' Region Puts the True Spirit of 'Xia' to the Test
Published on 11/13/2026 at 11:35, 2 hours 39 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 hours 39 minutes ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 6 hours 14 minutes ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 15 hours 1 minute ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 23:12, 15 hours 1 minute ago Belgrano poursuit la mise en oeuvre de son projet d'OPRA
